We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Reneo Pharmaceuticals Inc (RPHM) USD0.0001

Sell:$1.63 Buy:$1.74 Change: No change
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$1.63
Buy:$1.74
Change: No change
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$1.63
Buy:$1.74
Change: No change
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

Contact details

Address:
18575 Jamboree Road, Suite 275-S
IRVINE
92612
United States
Telephone:
+1 (858) 2830280
Website:
https://reneopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RPHM
ISIN:
US75974E1038
Market cap:
$54.96 million
Shares in issue:
33.31 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Grey
    Executive Chairman of the Board
  • Gregory Flesher
    President, Chief Executive Officer, Director
  • Niall O'Donnell
    Co-Founder, Director
  • Michael Cruse
    Chief Operating Officer
  • Alejandro Dorenbaum
    Chief Medical Officer
  • Ashley Hall
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.